Lactobacillus rhamnosus GG (ATCC 53103) for the Management of Infantile Colic: A Randomized Controlled Trial

Abstract

Background: The aim of this study was to investigate the efficacy of Lactobacillus rhamnosus ATCC 53103 together with the maternal diet avoidance of cow’s milk in treating infantile colic. Methods: Forty-five colicky breastfed infants were consecutively randomized to receive L. rhamnosus for 28 days at a dosage of 5 × 109 cfu per day or placebo. Faecal samples were collected from each subject before starting supplementation and at the end of the study period and were immediately analysed. Faecal calprotectin was detected via a quantitative assay. The total bacterial load and selected bacterial species were evaluated using real-time TaqMan PCR. Results: After supplementation for 28 days with Lactobacillus rhamnosus ATCC 53103, median full-force daily crying was reduced (104 versus 242 min, p < 0.001) and the values of faecal calprotectin decreased significantly (p = 0.026). Furthermore, the probiotic increased the abundance of Lactobacillus (p = 0.048) and total bacteria (p = 0.040); all these effects were not observed in the placebo group. Conclusion: Infants treated with Lactobacillus rhamnosus ATCC 53103 for 28 days, in association with the elimination of cow’s milk from the maternal diet, presented some interesting features related to the effect of this probiotic treatment: reductions in crying time and faecal calprotectin, with increased total bacteria and Lactobacillus. To validate these results, a double-blind, placebo-controlled trial on a larger cohort is required.

Oral and Intestinal Bacterial Substances Associated with Disease Activities in Patients with Rheumatoid Arthritis: A Cross-Sectional Clinical Study

“…Total bacteria counts were inversely correlated with serum LPS level and correlated with ENC levels (Table 5). Intestinal total bacteria counts are lower in animal models of obesity [48] and inflammatory bowel disease [49] and higher in animals treated with prebiotics [50] and probiotics [51,52]. Hence, lower total bacteria counts may indicate dysbiosis, which can cause gut barrier destruction resulting in higher intestinal absorption of bacteria toxins such as LPS and lower ENC levels by neutralizing absorbed LPS.…”

Probiotic Properties of Bifidobacterium longum KABP042 and Pediococcus pentosaceus KABP041 Show Potential to Counteract Functional Gastrointestinal Disorders in an Observational Pilot Trial in Infants

“…Insights about gut barrier disfunction and microbiome perturbations in the pathophysiology of FGIDs support a strong rationale to use specific probiotic strains as potential therapies due to their interactions with host intestinal epithelium and microbes among other roles ( Pärtty et al, 2018 ). A number of strains have been proposed for the management of pediatric FGIDs ( Wojtyniak and Szajewska, 2017 ; Sung et al, 2018 ; Nocerino et al, 2020 ; Savino et al, 2020 ). However, no specific probiotic strains have gained enough clinical evidence to be recommended by experts except for Limosilactobacillus reuteri DSM 17938 but only in breastfed babies subgroup ( Tabbers et al, 2014 ; Guarner et al, 2017 ; Martinelli et al, 2020 ).…”

Biotechnological Processes Simulating the Natural Fermentation Process of Bee Bread and Therapeutic Properties—An Overview

“…Multiple human and animal studies have been conducted and suggest that probiotics are GRAS and practical for clinical application on human diseases, such as acute pediatric diarrhea ( 138 ), rotavirus-related diarrhea ( 139 ), infantile colic ( 140 ), necrotizing enterocolitis in shallow birth weight infants ( 141 ), type 1 diabetes ( 142 ), allergic asthma ( 143 ) inflammatory bowel disease ( 144 ), bone loss ( 145 ), and bacterial vaginosis ( 146 ), and virus infection ( 147 ). Further details can be seen in Table 6 .…”